Aspergillosis – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Aspergillosis – Pipeline Review, H2 2019’, provides an overview of the Aspergillosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Aspergillosis

– The report reviews pipeline therapeutics for Aspergillosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Aspergillosis therapeutics and enlists all their major and minor projects

– The report assesses Aspergillosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Aspergillosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Aspergillosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABIONYX Pharma SA

Acea Biotech Inc

Amplyx Pharmaceuticals Inc

Argenx SE

Basilea Pharmaceutica Ltd

Bio-Synectics Inc

Biosergen AS

Cidara Therapeutics Inc

F2G Ltd

Galephar Pharmaceutical Research Inc

iCo Therapeutics Inc

Jiangsu Aosaikang Pharmaceutical Co Ltd

Matinas BioPharma Holdings Inc

Merck & Co Inc

Molecular Express Inc

Mycovia Pharmaceuticals Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Shaanxi Synthetic Pharmaceutical Co Ltd

TFF Pharmaceuticals Inc

Trilogy Therapeutics Inc

Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aspergillosis - Overview

Aspergillosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Aspergillosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aspergillosis - Companies Involved in Therapeutics Development

ABIONYX Pharma SA

Acea Biotech Inc

Amplyx Pharmaceuticals Inc

Argenx SE

Basilea Pharmaceutica Ltd

Bio-Synectics Inc

Biosergen AS

Cidara Therapeutics Inc

F2G Ltd

Galephar Pharmaceutical Research Inc

iCo Therapeutics Inc

Jiangsu Aosaikang Pharmaceutical Co Ltd

Matinas BioPharma Holdings Inc

Merck & Co Inc

Molecular Express Inc

Mycovia Pharmaceuticals Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Shaanxi Synthetic Pharmaceutical Co Ltd

TFF Pharmaceuticals Inc

Trilogy Therapeutics Inc

Visterra Inc

Aspergillosis - Drug Profiles

Aspergillosis - Dormant Projects

Aspergillosis - Discontinued Products

Aspergillosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Aspergillosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Aspergillosis – Pipeline by ABIONYX Pharma SA, H2 2019

Aspergillosis – Pipeline by Acea Biotech Inc, H2 2019

Aspergillosis – Pipeline by Amplyx Pharmaceuticals Inc, H2 2019

Aspergillosis – Pipeline by Argenx SE, H2 2019

Aspergillosis – Pipeline by Basilea Pharmaceutica Ltd, H2 2019

Aspergillosis – Pipeline by Bio-Synectics Inc, H2 2019

Aspergillosis – Pipeline by Biosergen AS, H2 2019

Aspergillosis – Pipeline by Cidara Therapeutics Inc, H2 2019

Aspergillosis – Pipeline by F2G Ltd, H2 2019

Aspergillosis – Pipeline by Galephar Pharmaceutical Research Inc, H2 2019

Aspergillosis – Pipeline by iCo Therapeutics Inc, H2 2019

Aspergillosis – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2019

Aspergillosis – Pipeline by Matinas BioPharma Holdings Inc, H2 2019

Aspergillosis – Pipeline by Merck & Co Inc, H2 2019

Aspergillosis – Pipeline by Molecular Express Inc, H2 2019

Aspergillosis – Pipeline by Mycovia Pharmaceuticals Inc, H2 2019

Aspergillosis – Pipeline by Nanomerics Ltd, H2 2019

Aspergillosis – Pipeline by Novabiotics Ltd, H2 2019

Aspergillosis – Pipeline by Pulmatrix Inc, H2 2019

Aspergillosis – Pipeline by Pulmocide Ltd, H2 2019

Aspergillosis – Pipeline by Scynexis Inc, H2 2019

Aspergillosis – Pipeline by Sealife PHARMA GMBH, H2 2019

Aspergillosis – Pipeline by Shaanxi Synthetic Pharmaceutical Co Ltd, H2 2019

Aspergillosis – Pipeline by TFF Pharmaceuticals Inc, H2 2019

Aspergillosis – Pipeline by Trilogy Therapeutics Inc, H2 2019

Aspergillosis – Pipeline by Visterra Inc, H2 2019

Aspergillosis – Dormant Projects, H2 2019

Aspergillosis – Dormant Projects, H2 2019 (Contd..1), H2 2019

Aspergillosis – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Aspergillosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports